Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
about
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic StrategiesKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsVemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemiaInhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemiaEffect of lentivirus-mediated survivin transfection on the morphology and apoptosis of nucleus pulposus cells derived from degenerative human disc in vitroTargeting survivin and p53 in pediatric acute lymphoblastic leukemia.Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLSerum Survivin and TP53 Gene Expression in Children with Acute Lymphoblastic Leukemia.BIRC6 mediates imatinib resistance independently of Mcl-1.Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AMLMultifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.Apoptosis in leukemias: regulation and therapeutic targeting.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Transcriptional regulation of the survivin gene.Survivin as a preferential target for cancer therapy.SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells.Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cellsLQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells.Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy.Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin.Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.
P2860
Q26766250-769575BD-B62C-40DE-85D4-FD23B08E0575Q26849792-4706D398-23CE-4512-B03E-F2F994F45CB6Q27852401-E7A20448-F830-410E-B045-E8B88444A995Q28485864-B0449A22-1341-4BB4-9B2A-9986CCC07D08Q34167708-486246CE-D649-495C-8445-84F3F2A9CEECQ35119355-97242EB9-E193-4B2E-9E43-4B09960047A0Q35170707-24B475E7-7F2E-40FF-9F3D-579DFA7C0C8DQ35195759-63D2A210-A93D-4C1A-A1E6-4A5C9FCA65CDQ35827627-8484BC19-C402-42A1-9F27-494B2F517766Q35999249-C10BB0A4-0737-44E7-AEBD-DF83777E5204Q36079787-FDADC4FE-EF07-492C-99E1-076E3AA4BA13Q36348778-A5520D0E-F5A7-459D-93B2-9F7052D4D2ECQ36375641-BE8B45C1-A4B9-41AB-9293-D059A6E51077Q36686170-5F743085-F861-49A1-B4CD-493517EB921CQ36686176-7506D5A6-CF17-4095-BEEF-3657A19157C0Q36804432-A56E9CC6-5CB8-4A05-812C-7C5F6B432446Q37233609-4B43DDF2-0FFC-40F0-B04E-CE918F596988Q37440054-ED1FF4A3-8049-4C12-B5A3-A0610B7513C6Q37634505-E0087ED1-9D5F-4800-875E-80FCF27DC20AQ37715814-E98235EC-0EE2-47B5-8A47-131395E077FDQ37773256-08C7246F-E964-421E-8494-9A64C06EE407Q38160371-77B0E21D-9604-490D-BE64-BDCDBAFB7513Q38188377-917F9555-E87D-4C0A-857D-FB4F80C69902Q39063028-FA39F4D7-8886-4639-8B6A-6BE06E9DC47AQ39673400-C3986E26-40A1-491D-B88F-2BA6C6DB0997Q39700748-BC58629E-BE97-4FE8-8E58-2576CC21C6DBQ39825470-3A20A043-3684-4293-85C9-406F19974ED8Q40141913-60B06B29-448D-4F6E-B220-4A852C4FC5F3Q41335233-6D08D86E-8DB9-4A06-803E-592EDD2A2D21Q41842515-952E2E5A-9E1F-41F4-A8DF-7B6A72C7A5BAQ48227330-D360EAF9-706A-4DEC-B0B9-E741CB9FF9FD
P2860
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Regulation of survivin express ...... imatinib-responsive CML cells.
@en
type
label
Regulation of survivin express ...... imatinib-responsive CML cells.
@en
prefLabel
Regulation of survivin express ...... imatinib-responsive CML cells.
@en
P2093
P2860
P1433
P1476
Regulation of survivin express ...... imatinib-responsive CML cells.
@en
P2093
Bing Z Carter
Duncan H Mak
Maria Cabreira-Hansen
Miloslav Beran
Teresa McQueen
Wendy D Schober
Wenjing Chen
P2860
P304
P356
10.1182/BLOOD-2004-12-4704
P407
P577
2005-10-27T00:00:00Z